Recurrent Ovarian Cancer Clinical Trials 2024

Recurrent Ovarian Cancer Clinical Trials 2024

Recurrent Ovarian Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in recurrent ovarian cancer clinical trials today.

Recurrent Ovarian Cancer Clinical Trials

Here are the 6 most popular medical studies for recurrent ovarian cancer

Popular filter options for recurrent ovarian cancer trials

Ovarian Cancer Clinical Trials

View 70 Ovarian Cancer medical studies.

SOC Clinical Trials

View 70 SOC medical studies.

Metastatic Recurrent Ovarian Cancer Clinical Trials

View 71 metastatic recurrent ovarian cancer medical studies.

BRCA Positive Clinical Trials

View 8 BRCA positive medical studies.

BRCA1 Positive Clinical Trials

View 7 BRCA1 positive medical studies.

Phase 3 Recurrent Ovarian Cancer Clinical Trials

View 71 phase 3 recurrent ovarian cancer medical studies.

Recurrent Ovarian Cancer Clinical Trials With No Placebo

View 71 recurrent ovarian cancer medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to recurrent ovarian cancer

What are the top hospitals conducting recurrent ovarian cancer research?

When it comes to combatting recurrent ovarian cancer, several remarkable hospitals are leading the way with their dedication to innovative clinical trials. One such institution is the M D Anderson Cancer Center located in Houston. With 11 active trials specifically targeting recurrent ovarian cancer, this center focuses on finding new treatments and potential cures for this challenging condition. Meanwhile, the University of Colorado Hospital in Aurora is also making significant strides with nine ongoing trials dedicated to recurrent ovarian cancer patients. These hospitals are at the forefront of pioneering research efforts and aim to improve outcomes for those affected by this disease.

In addition to these centers, Mayo Clinic in Rochester has eight active clinical trials underway that directly address recurrent ovarian cancer. This renowned clinic's commitment towards finding better therapies and understanding the intricacies of this illness cannot be understated. Similarly, the University of Chicago Comprehensive Cancer Center prides itself on its eight current clinical trials focused solely on combating recurrent ovarian cancer. Their expertise and dedication make them a formidable force in advancing knowledge about this complex disease.

Lastly, we have the University of Pittsburgh Cancer Institute (UPCI) situated in Pittsburgh—a hospital that shares equal passion among other top institutions when it comes to fighting against recurrence from ovarian cancers—boasting eight active clinical trials targeting this specific aspect as well.

Although these hospitals may not have conducted any previous studies devoted explicitly to recurring cases yet due perhaps being relatively young or recent additions within domain regardless their exceptional focus today signifies great promise for progress moving forward into future years ahead- granting renewed hope countless patients across nation can rely upon!

Which are the best cities for recurrent ovarian cancer clinical trials?

When it comes to recurrent ovarian cancer clinical trials, several cities have emerged as leading hubs for research and advancement. Anchorage, Alaska takes the lead with 43 active trials investigating treatments like Bevacizumab, epacadostat, pembrolizumab, and Tazemetostat. Denver, Colorado closely follows with 42 ongoing studies focusing on similar interventions including Bevacizumab, epacadostat, pembrolizumab, and Nivolumab. Chicago in Illinois boasts 24 active trials examining pharmacological studies such as Paclitaxel and REGN5668. Additionally, Aurora in Colorado offers another 24 ongoing trials exploring options like Bevacizumab and NovoTTF-100L(O). Lastly, Los Angeles in California contributes significantly to the field with 23 active trials that delve into promising treatments involving Bevacizumab, Paclitaxel ,and targeted therapies for MET exon 14 deletion/mutations. These cities represent hotspots of research where individuals battling recurrent ovarian cancer can access cutting-edge clinical trials offering hope for improved outcomes.

Which are the top treatments for recurrent ovarian cancer being explored in clinical trials?

When it comes to recurrent ovarian cancer, clinical trials are shedding light on several promising treatments. Leading the pack is niraparib, a drug currently being explored in six active trials dedicated to tackling this challenging disease. Another contender making waves is olaparib, with four ongoing clinical trials focused specifically on recurrent ovarian cancer. Rucaparib also shows promise with its involvement in three active studies for this condition. These innovative therapies offer hope for patients as researchers strive to find effective solutions against recurrent ovarian cancer.

What are the most recent clinical trials for recurrent ovarian cancer?

Exciting advancements are being made in the field of recurrent ovarian cancer, with recent clinical trials offering potential breakthroughs for patients. One notable trial explores a combination treatment approach involving apheresis, FRalphaDC, and pembrolizumab. Another study focuses on the efficacy of CPI-0209 (150 mg) alongside carboplatin. Additionally, pembrolizumab has shown promise as a standalone treatment option for recurrent ovarian cancer. Furthermore, Arm I investigates the effectiveness of selumetinib and olaparib in combating this form of cancer. Lastly, EAY191-E5 Cohort II examines sotorasib's impact on recurrent ovarian cancer. These trials offer hope for improved outcomes and enhanced quality of life for individuals battling this challenging disease.

What recurrent ovarian cancer clinical trials were recently completed?

Several clinical trials investigating new treatments for recurrent ovarian cancer have recently concluded, presenting promising prospects in the fight against this challenging disease. Notably, a trial sponsored by the National Cancer Institute (NCI) centered on the study of Olaparib and Cediranib combination therapy reached completion in May 2021. Additionally, another NCI-sponsored trial exploring Rucaparib as maintenance therapy concluded in July 2021. These significant developments highlight the ongoing efforts to advance treatment options for patients with recurrent ovarian cancer and bring hope for improved outcomes in the future.